Immune checkpoint inhibitors and allogeneic transplant in lymphoid malignancies: a deceptive friend story

Allogeneic transplantation after PD-1 blockade for classic Hodgkin lymphoma

(2021) Reid W. Merryman et al.   LEUKEMIA

Molecular biology of Hodgkin lymphoma

(2021) Marc A. Weniger et al.   LEUKEMIA

Use of checkpoint inhibitors in patients with lymphoid malignancies receiving allogeneic cell transplantation: a review

(2021) Sabela Bobillo et al.   BONE MARROW TRANSPLANTATION

Potential survival benefit for patients receiving allogeneic hematopoietic stem cell transplantation after nivolumab therapy for relapse/refractory Hodgkin lymphoma: Real-life experience in Spain (Spanish Group of Lymphoma and Bone Marrow Transplantation, GELTAMO)

(2020) Carmen Martínez et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Non-Myeloablative Allogeneic Transplantation with Post-Transplant Cyclophosphamide after Immune Checkpoint Inhibition for Classic Hodgkin Lymphoma: A Retrospective Cohort Study

(2020) Suman Paul et al.   BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION

Safety and efficacy of anti-programmed cell death-1 monoclonal antibodies before and after allogeneic hematopoietic cell transplantation for relapsed or refractory Hodgkin lymphoma: a multicenter retrospective study

(2020) Ayumu Ito et al.   INTERNATIONAL JOURNAL OF HEMATOLOGY

Pembrolizumab in relapsed or refractory Hodgkin lymphoma: 2-year follow-up of KEYNOTE-087

(2019) Robert Chen et al.   BLOOD

Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma

(2019) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Recommendations for managing PD-1 blockade in the context of allogeneic HCT in Hodgkin lymphoma: taming a necessary evil

(2018) Charles Herbaux et al.   BLOOD

Allogeneic hematopoietic stem cell transplantation in Hodgkin lymphoma: a systematic review and meta-analysis

(2016) A Rashidi et al.   BONE MARROW TRANSPLANTATION

Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure

(2016) Philippe Armand et al.   JOURNAL OF CLINICAL ONCOLOGY

Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial

(2016) Anas Younes et al.   LANCET ONCOLOGY

Post-Transplantation Cyclophosphamide for Tolerance Induction in HLA-Haploidentical Bone Marrow Transplantation

(2012) Leo Luznik et al.   SEMINARS IN ONCOLOGY